Table 4. Details of No. positive patients.
No. | No. of metastatic LNs | Regional LNs | Station of metastatic LNs | Tumor size in preoperative EGD | Tumor size in pathology | Depth of invasion | Differentiation | Ulceration | LVI | ESD indication |
---|---|---|---|---|---|---|---|---|---|---|
1 | 4 | LAP (3b, 4d, 5, 6) | 6, 8a, 9 | 2 | 6.2 | SM2 | WD | (+) | (+) | Beyond |
2 | 2 | LLC (3b, 5) | 1, 6 | 2 | 2.8 | SM2 | PD | (−) | (+) | Beyond |
3 | 2 | MGC (4sb, 4d) | 4d (RLN) | 1.3 | 2 | M | SRC | (−) | (−) | Expanded |
4 | 1 | LAP (3b, 4d, 5, 6) | 6 (RLN) | 1.2 | 0.8 | M | MD | (−) | (+) | Beyond |
LN = lymph node; EGD = esophagogastroduodenoscopy; LVI = lymphovascular invasion; ESD = endoscopic submucosal dissection; LAP = lower anterior or posterior; SM = submucosa; M = mucosa; WD = well differentiated; LLC = lower lesser curvature; PD = poorly differentiated; MGC = middle greater curvature; RLN = regional lymph node; SRC = signet ring cell; MD = moderately differentiated.